<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220515054856N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-07-23</date_registration>
      <primary_sponsor>Kerman University of Medical Sciences</primary_sponsor>
      <public_title>Determining the effects of mouthwash from areal parts Alhagi sp. aerial parts extract on paraquat-induced oral ulcers in poisoned patients</public_title>
      <acronym></acronym>
      <scientific_title>Determining the effects of mouthwash from areal parts Alhagi sp. aerial parts extract on paraquat-induced oral ulcers in poisoned patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>45</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/64140</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Other, Randomization description: Randomization of the unit is done by block method with a block size of 4. For each of the 6 possible states for the quadruple block, the numbers are assigned as follows: ABBA (3), ABAB (2), AABB (1), BAAB (6), BABA (5), BBAA (4) using the table Random numbers, numbers between 1 and 6 are selected and the treatment allocation list is specified according to each number. To execute the generated random sequence, the method of hiding encoded boxes or cans is used. In this method, the cans are numbered according to a random sequence and inside the boxes, the desired intervention (drug) or a sheet on which the random allocation is written, is provided to the executor with the condition that the boxes are completely sealed and The researcher assigns patients to the standard intervention and treatment group based on the order of patients' admission. Tools: Creating a random sequence of 4 hiding random blocks to execute a random sequence on study participants. How to build: Randomly select the block and read the letters from right to left. The cans are the same weight and shape and will be prepared by an independent researcher.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Paraquat herbicide poisoning.</hc_freetext>
      <i_freetext>Intervention 1: The first intervention group: Triamcinolone paste (made in Iran, manufacturer: Emad Darman Pars Chemical formula: C21H27FO6) which is given to the patient 3 times a day (every 8 hours) every day for a month to cover the wound surface. Intervention 2: The second intervention group : Aluminum hydroxide mouthwash + lidocaine + diphenhydramine (made in Iran, manufacturer: Iran Hormone), each person is given 10 cc 3 times a day for one month (once every 8 hours). Intervention 3: The third intervention group: Alhagi mouthwash (containing 0.1% of Kharshtar plant extract, made in the laboratory of the Faculty of Pharmacy of Kerman University of Medical Sciences) which is given to each person 3 times a day(once every 8 hours) for one  month,amount of 10 CC is given from it.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Total data

When:
Starting from 6 months after the publication of the article

To whom:
Researchers, students and doctors

Conditions:
To conduct a clinical trial

Where to obtain:
General or scientific responsible person

How to obtain:
Send the proposal to the email of the person in charge

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Kerman University of Medical Sciences</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kerman, the beginning of Haft Bagh Alavi axis, campus of University of Medical Sciences</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7616913555</zip>
        <telephone>+98 34 3132 5700</telephone>
        <email>nairimajdfaranak@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Faranak Nasiri Majd</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kerman, the beginning of Haft Bagh Alavi axis, campus of University of Medical Sciences</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7616913555</zip>
        <telephone>+98 34 3132 5700</telephone>
        <email>nasirimajdfaranak@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Definitive use of paraquat herbicide with toxic dose (based on history, clinical examination, endoscopic findings)
Patient consent to participate in the study</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Poisoning with other herbicides other than paraquat (based on history, clinical examination, endoscopic findings)
Non-toxic dose of paraquat (endoscopy and normal tests)
Patient dissatisfaction to participate in the study
Patients do not cooperate to take medicine due to mouth ulcers</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The first intervention group: Triamcinolone paste (made in Iran, manufacturer: Emad Darman Pars Chemical formula: C21H27FO6) which is given to the patient 3 times a day (every 8 hours) every day for a month to cover the wound surface.</i_keyword>
      <i_keyword>The second intervention group : Aluminum hydroxide mouthwash + lidocaine + diphenhydramine (made in Iran, manufacturer: Iran Hormone), each person is given 10 cc 3 times a day for one month (once every 8 hours).</i_keyword>
      <i_keyword>The third intervention group: Alhagi mouthwash (containing 0.1% of Kharshtar plant extract, made in the laboratory of the Faculty of Pharmacy of Kerman University of Medical Sciences) which is given to each person 3 times a day(once every 8 hours) for one  month,amount of 10 CC is given from it.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The rate of change (decrease or increase) in the size of oral lesions. Timepoint: 3, 7 and 30 days after patient visit and discharge time. Method of measurement: Pemphigus Oral Lesions Intensity Score (POLIS) Questionnaire.</prim_outcome>
      <prim_outcome>Evaluation of difficulty in eating due to its consistency. Timepoint: At the beginning of the study (before the intervention) and 3, 7 and 30 days after the patient's visit and discharge time. Method of measurement: Pemphigus Oral Lesions Intensity Score (POLIS) Questionnaire.</prim_outcome>
      <prim_outcome>Check the Speech Problem. Timepoint: At the beginning of the study (before the intervention) and 3, 7 and 30 days after the patient's visit and discharge time. Method of measurement: Pemphigus Oral Lesions Intensity Score (POLIS) Questionnaire.</prim_outcome>
      <prim_outcome>Check for discomfort when opening and moving the mouth. Timepoint: At the beginning of the study (before the intervention) and 3, 7 and 30 days after the patient's visit and discharge time. Method of measurement: Pemphigus Oral Lesions Intensity Score (POLIS) Questionnaire.</prim_outcome>
      <prim_outcome>Check for swallowing problems. Timepoint: At the beginning of the study (before the intervention) and 3, 7 and 30 days after the patient's visit and discharge time. Method of measurement: Pemphigus Oral Lesions Intensity Score (POLIS) Questionnaire.</prim_outcome>
      <prim_outcome>Check the number of areas involved in the oral cavity. Timepoint: At the beginning of the study (before the intervention) and 3, 7 and 30 days after the patient's visit and discharge time. Method of measurement: Pemphigus Oral Lesions Intensity Score (POLIS) Questionnaire.</prim_outcome>
      <prim_outcome>Measuring pain intensity. Timepoint: At the beginning of the study (before the intervention) and 3, 7 and 30 days after the patient's visit and discharge time. Method of measurement: Questionnaire,The Numeric Pain Rating Scale (NPRS).</prim_outcome>
      <prim_outcome>Recovery time. Timepoint: From the beginning until the recovery every 4 days. Method of measurement: follow up(Examining the patient and asking the patient).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kerman University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-06-12</approval_date>
        <contact_name>Ethics Committee of Kerman University of Medical Sciences</contact_name>
        <contact_address>The beginning of Haft Bagh Alavi axis, campus of University of Medical Sciences kerman Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
